FSEG - ETF AI Analysis
Top Page
Fidelity Enhanced Small Cap Growth ETF (FSEG)
FSEG, the Fidelity Enhanced Small Cap Growth ETF, has a solid overall rating driven by several strong holdings with healthy financial performance and growth prospects, such as Abercrombie & Fitch, Balchem, Plexus, and Moog, which benefit from robust profitability, strategic initiatives, and positive earnings outlooks. However, weaker positions like Oscar Health and Twist Bioscience, which face profitability, cash flow, and bearish technical challenges, weigh on the fund’s rating. The main risk factor is its focus on smaller growth companies, where financial and valuation volatility can be higher and some holdings show signs of potential overvaluation or overbought conditions.
FSEG vs. SPDR S&P 500 ETF (SPY)
- AUM
- 7.73M
- Region
- North America
- Expense Ratio
- 0.28%
- Beta
- 1.17
- Issuer
- Fidelity
- Inception Date
- Apr 28, 2026
- Dividend Yield
- 0.08%
- Asset Class
- Equity
- Index Tracked
- No Underlying Index
FSEG Summary
Fidelity Enhanced Small Cap Growth ETF (FSEG) focuses on fast-growing smaller U.S. companies, using the Russell 2000 Growth Index as its starting point. It is actively managed, meaning the managers pick and weight stocks they believe have strong growth potential, mainly in health care and technology. Well-known names in the fund include Abercrombie & Fitch and Oscar Health. An investor might choose this ETF for the chance of higher long-term growth and added diversification beyond large, well-known stocks. However, because it invests in small, growth-focused companies, its price can be more volatile and may rise or fall sharply with market conditions.
How much will it cost me?
This ETF has an expense ratio of 0.28%, which means you’ll pay about $2.80 per year for every $1,000 invested. That’s a bit higher than the average index ETF because it’s actively managed, with managers selecting small-cap growth stocks in an effort to outperform the market.
What would affect this ETF?
This ETF could benefit if the U.S. economy stays healthy, investor appetite for smaller growth companies improves, and trends in technology and health care remain strong, supporting many of its key holdings. On the other hand, it could be hurt by rising interest rates, a downturn in small-cap stocks, regulatory or reimbursement changes in health care, or a pullback in high-growth tech names, all of which can make its concentrated small-cap growth exposure more volatile.
FSEG Top 10 Holdings
FSEG is leaning hard into U.S. small-cap growth, with a clear tilt toward health care and tech names that can really move the needle. Twist Bioscience and MaxLinear have been rising and look like key engines for recent performance, while Oscar Health and Glaukos are more mixed, with promising growth stories but profitability issues that can hold the fund back. Industrial players like Materion and Moog add a steadier, cyclical backbone. Overall, this is a domestically focused, high-conviction small-cap growth basket where a few volatile winners and laggards drive the ride.
| Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
 GKOS | Glaukos | 1.10% | $84.81K | $10.43B | 130.58% | 61Neutral |
 OSCR | Oscar Health | 1.05% | $81.42K | $10.39B | 63.57% | 49Neutral |
 PLXS | Plexus | 0.87% | $67.39K | $6.30B | 51.12% | 75Outperform |
 ANF | Abercrombie Fitch | 0.88% | $67.76K | $6.77B | 136.13% | 78Outperform |
 ENS | EnerSys | 0.81% | $62.44K | $6.15B | 41.63% | 79Outperform |
 YOU | Clear Secure | 0.82% | $63.60K | $6.15B | 40.28% | 77Outperform |
 BTSG | BrightSpring Health Services, Inc. | 0.95% | $73.22K | $12.35B | 84.76% | 67Neutral |
 BGC | BGC Group | 0.78% | $60.30K | $5.51B | 27.85% | 65Neutral |
 BCPC | Balchem | 0.75% | $57.66K | $5.47B | 10.32% | 75Outperform |
 KLIC | Kulicke & Soffa | 0.73% | $56.38K | $4.26B | 90.60% | 61Neutral |
FSEG Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For FSEG, the sentiment is Negative. The current price of 25.60 is below the 20-day moving average (MA) of 25.92, below the 50-day MA of 26.59, and compared to the 200-day MA of , indicating a neutral trend. The MACD of -0.27 indicates Negative momentum. The RSI at 43.81 is Neutral, neither overbought nor oversold. The STOCH value of 61.72 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FSEG.
FSEG Peer Comparison
Comparison Results
| Name | Price | Price Target | AUM | Expense Ratio | Overall Rating |
|---|---|---|---|---|---|
| FSEG | $25.60 | $28.00(9.36% Upside) | $7.73M | 0.28% | 62Neutral |
 ACSG | $45.23 | $64.23(42.02% Upside) | $53.77M | 0.49% | 63Neutral |
 TMFS | $34.17 | $43.66(27.77% Upside) | $52.03M | 0.85% | 62Neutral |
 MMSC | $25.82 | $35.09(35.91% Upside) | $51.30M | 0.95% | 64Neutral |
 SGRW | $23.85 | $36.01(50.97% Upside) | $27.35M | 0.80% | 60Neutral |
 SAWS | $22.04 | $28.69(30.19% Upside) | $7.21M | 0.55% | 71Outperform |
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| FSEG | Fidelity Enhanced Small Cap Growth ETF | 25.60 | 0.38 | 1.49% | |
| ACSG | American Century Small Cap Growth Insights ETF | 45.23 | 3.66 | 8.80% | |
| TMFS | Motley Fool Small-Cap Growth ETF | 34.17 | -0.58 | -1.67% | |
| MMSC | First Trust Multi-Manager Small Cap Opportunities ETF | 25.82 | 1.35 | 5.53% | |
| SGRW | Harbor Active Small Cap Growth ETF | 23.85 | 3.56 | 17.54% | |
| SAWS | AAM Sawgrass US Small Cap Quality Growth ETF | 22.04 | 0.59 | 2.77% |
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.